News Releases

News and information from The Leukemia & Lymphoma Society

LLS Expands Hurricane Relief Effort

(Rye Brook, NY – September 13, 2017) –The Leukemia & Lymphoma Society (LLS) today announced the extension of its hurricane relief  program set up last week to assist blood cancer patients in Texas and Louisiana affected by Hurricane Harvey, to provide direct support to blood cancer patients hit by Hurricane Irma. The world’s largest non-profit dedicated to fighting blood cancers, LLS committed up to $1...

LLS Commits $1 Million to Blood Cancer Patients Impacted by Hurricane Harvey

Rye Brook, NY – September 5, 2017 – In the wake of the destruction caused by Hurricane Harvey, The Leukemia & Lymphoma Society (LLS) announced today that it will donate up to $1 million to help blood cancer patients who have been impacted by the storm. Blood cancer patients living in declared disaster areas impacted by Hurricane Harvey, are eligible to receive $500 to help with cancer-related necessities s...

FDA Approval of AML Therapy is a Significant Advance for Blood Cancer Patients

Rye Brook, N.Y. (September 1, 2017) – The steady march of progress in new treatments for patients with acute myeloid leukemia (AML), one of the most deadly blood cancers which takes more than 10,000 lives in the U.S. each year, continues today with the U.S. Food & Drug Administration approval of gemtuzumab ozogamicin (Mylotarg®). After four decades of little progress for this lethal disease, today’s ...

Survey Reveals Striking Lack of Knowledge of Major Cancer Killer

View full multimedia release here.  Rye Brook, NY (August 31, 2017) – Blood cancers are the third leading cause of cancer deaths in the U.S. However, many Americans are unaware of the impact of these cancers, including leukemia, lymphoma and myeloma, which affect the bone marrow, the blood cells, the lymph nodes and other parts of the lymphatic system. A new survey commissioned by The Leukemia &...

Pages

Media Contact

Have media inquiries? Contact us between 9 a.m. and 5 p.m. ET, Monday through Friday: